CATT: Comparison of Age-related macular degeneration Treatment TrialThis study compares two new treatments for age-related macular degeneration (AMD) Lucentis® and Avastin®. Both of these new medications have been used for treating “wet” AMD with great success, but there has never been a trial comparing the two until now.
Candidates must have “wet” AMD in at least one eye that has never had any previous treatment, and age 50 or older to be eligible (please note: there are other criteria to be met in order to enroll). The trial will last for 24 months, and participants will receive an injection of one of the two study drugs in their study eye either on a fixed monthly schedule or variable dosing schedule.
The following is a brief summary of inclusion/exclusion criterion in technical language. You may wish to share this information with your doctor to determine if you are eligible. Please note that this is not a complete list.
Inclusion:
- Age 50 or older
- Postmenopausal for at least 12 months, surgically sterile, or effective birth control (if applicable)
- Newly diagnosed active CNV secondary to AMD, not previously treated, in study eye
- Visual acuity 20/25-20/320 in study eye
Exclusion:
- History of submacular surgery or other surgical intervention for AMD in the study eye, or vitrectomy
- CNV in either eye due to other causes (POHS, pathologic myopia, trauma)
- History of retinal detachment or macular hole, or current vitreous hemorrhage in the study eye
- Intraocular surgery (including cataract surgery) in the study eye within 2 months preceding the first study treatment
- Uncontrolled glaucoma in the study eye (greater than or equal to 25)
- Pregnancy
- Evidence of significant uncontrolled concomitant disease (cardiovascular, pulmonary, renal, etc)
